SCHEMBL2864314

SCHEMBL2864314

c1ccc(Nc2c[nH]c3ccccc23)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
MAPT P10636 3/20 0.52
GAA P10253 3/20 0.52
TDP1 Q9NUW8 2/20 0.52
KDM4E B2RXH2 1/20 0.52
GLA P06280 1/20 0.52
RECQL P46063 1/20 0.52
PRKCB P05771 1/20 0.50
PRKCA P17252 1/20 0.50
PTGS1 P23219 1/20 0.49
PTGS2 P35354 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
SENP7 Q9BQF6 1/20 0.47
ATM Q13315 3/20 0.47
CYP3A4 P08684 2/20 0.47
ALDH1A1 P00352 2/20 0.47
HPGD P15428 2/20 0.47
TP53 P04637 1/20 0.47
ALOX15 P16050 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6654114 0.87 ATM (0.52) MEN1KMT2AMAPTTDP1KDM4E
SCHEMBL31744754 0.85 STING1 (0.49) PTGS1PTGS2STING1
SCHEMBL31744616 0.85 STING1 (0.64) MEN1KMT2AMAPTGAAKDM4E
SCHEMBL31744731 0.85 STING1 (0.64) MEN1KMT2APTGS2SENP7STING1
SCHEMBL31744748 0.85 STING1 (0.64) MEN1KMT2AMAPTGAATDP1
SCHEMBL5618628 0.85 IMPDH2 (0.53) MEN1KMT2AMAPTGAASMN1; SMN2
SCHEMBL28481543 0.82 TDP1 (0.46) MEN1KMT2AMAPTTDP1PRKCB
SCHEMBL31744663 0.81 STING1 (0.67) MEN1KMT2ATDP1PRKCBPTGS2
SCHEMBL31744824 0.81 RAB9A (0.56) MEN1KMT2AMAPTGAATDP1
SCHEMBL27872852 0.81 PTGS2 (0.56) MEN1KMT2APTGS2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250382268-A1 METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES CFD RES CORPORATION (US) 2025-12-18 US claimed
CN-108892634-B Indolylmethylaniline compound and application thereof 浙江工业大学 2021-04-23 CN claimed
CN-122055651-A Wavelength selective absorption filter and organic electroluminescent display device 富士胶片株式会社 2026-05-15 CN disclosed
US-20250382269-A1 METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES CFD RES CORPORATION (US) 2025-12-18 US disclosed
US-20250382268-A1 METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES CFD RES CORPORATION (US) 2025-12-18 US disclosed
CN-118732114-A Polarizing film, polarizing plate, and method for producing polarizing film 日东电工株式会社 2024-10-01 CN disclosed
CN-114761065-A Cosmetic method using microneedle sheet 莱雅公司 2022-07-15 CN disclosed
CN-105492424-B Indenoindole derivative and organic electroluminescence device 保土谷化学工业株式会社 2018-11-27 CN disclosed
CN-105492424-A Indenoindole derivative and organic electroluminescent element HODOGAYA CHEMICAL CO LTD 2016-04-13 CN disclosed
CN-1953982-B 4-substituted 1,5-dihydro-pyrido(3,2-b)indol-2-ones TIBOTEC PHARM LTD 2011-07-06 CN disclosed
CN-1976930-B 6,7,8,9-substituted 1-phenyl-1,5-dihydro-pyrido(3,2-b)indol-2-ones useful as anti-infective pharmaceutical agents TIBOTEC PHARM LTD 2011-01-19 CN disclosed
CN-1953982-A 4-substituted 1,5-dihydro-pyrido(3,2-b)indol-2-ones TIBOTEC PHARM LTD (IE) 2007-04-25 CN disclosed
CN-1953978-A 5-substituted 1-phenyl-1, 5-dihydro-pyrido [3, 2-B ] indol-2-ones and analogues thereof as antiviral agents TIBOTEC PHARM LTD (IE) 2007-04-25 CN disclosed
CN-1953983-A 1-heterocyclyl-1,5-dihydro-pyrido[3,2-b]indol-2-ones TIBOTEC PHARM LTD (IE) 2007-04-25 CN disclosed
EP-1758911-A1 1-HETEROCYCLYL-1,5-DIHYDRO-PYRIDO[3,2-B]INDOL-2-ONES Tibotec Pharmaceuticals Ltd. (IE) 2007-03-07 EP disclosed
EP-1751165-A1 4-SUBSTITUTED 1,5-DIHYDRO-PYRIDO(3,2-B)INDOL-2-ONES Tibotec Pharmaceuticals Ltd. (IE) 2007-02-14 EP disclosed
EP-1751154-A1 5-SUBSTITUTED 1-PHENYL-1,5-DIHYDRO-PYRIDO[3,2-B] INDOL-2-ONES AND ANALOGS AS ANTI-VIRALS Tibotec Pharmaceuticals Ltd. (IE) 2007-02-14 EP disclosed
WO-2005111034-A1 5-SUBSTITUTED 1-PHENYL-1,5-DIHYDRO-PYRIDO’3,2-B! INDOL-2-ONES AND ANALOGS AS ANTI-VIRALS TIBOTEC PHARMACEUTICALS LTD. (IE) 2005-11-24 WO disclosed
WO-2005111044-A1 4-SUBSTITUTED-1,5-DIHYDRO-PYRIDO[3,2-B]INDOL-2-ONES TIBOTEC PHARMACEUTICALS LTD. (IE) 2005-11-24 WO disclosed
WO-2005111047-A1 1-HETEROCYCLYL-1,5-DIHYDRO-PYRIDO[3,2-B]INDOL-2-ONES TIBOTEC PHARMACEUTICALS LTD. (IE) 2005-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250382269-A1 METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES CD14, MIF, NOD2 MEN1 2402/4885KMT2A 4633/4885MAPT 48/4885
US-20250382268-A1 METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES CD14, MIF, NOD2 MEN1 2402/4885KMT2A 4633/4885MAPT 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.